Ruxolitinib in polycythemia vera: Follow-up from the RESPONSE trial.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Masayuki Hino, Beatriz Moiraghi, Carole Brennan Miller, Vittorio Rosti, Ruben A. Mesa, Mark M. Jones, Huiling Zhen, Jingjin Li, Nathalie Francillard, Dany Habr, Jean-Jacques Kiladjian
Institutions: The University of Texas MD Anderson Cancer Center, University of Florence, Johannes Wesling Klinikum Minden, Unified Szent István and Szent László Hospital, Royal Brisbane and Women's Hospital, Ospedale di Circolo e Fondazione Macchi, Guy's and St Thomas' NHS Foundation Trust, University of Naples Federico II, Ziekenhuisnetwerk Antwerpen Stuivenberg, The University of Osaka, Hospital Ramos Mejía, Saint Agnes Hospital, Policlinico San Matteo Fondazione, Mayo Clinic, Mayo Clinic in Arizona, Incyte (United States), Novartis (France), Hôpital Saint-Louis, Université Paris Diderot
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2603736070